Develops novel oncology therapeutics that target cancer stem cell pathways and immuno-oncology mechanisms to inhibit tumor initiation, growth, metastasis and recurrence. Maintains a clinical-stage pipeline of internally discovered drug candidates and active preclinical programs to expand treatment options for cancer patients.